[HTML] thelancet.comFull View

[HTML][HTML] Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis

CT Bramante, NE Ingraham, TA Murray… - The Lancet Healthy …, 2021 - thelancet.com
Background Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …
被引用次数：185 相关文章

Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis

CT Bramante, NE Ingraham, TA Murray… - The Lancet Healthy …, 2021 - experts.umn.edu
Background: Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …
[HTML] sld.cu

[HTML][HTML] Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis

CT Bramante, NE Ingraham, TA Murray… - The Lancet Healthy …, 2021 - covid19.sld.cu
Background Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …

Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis

CT Bramante, NE Ingraham… - The lancet. Healthy …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …

Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis

CT Bramante, NE Ingraham… - The Lancet Healthy …, 2021 - scholarship.miami.edu
Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors for severe
COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory effects …

Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.

CT Bramante, NE Ingraham, TA Murray… - The lancet. Healthy …, 2020 - europepmc.org
Background Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …
[HTML] thelancet.com

[HTML][HTML] Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis

CT Bramante, NE Ingraham, TA Murray… - The Lancet Healthy …, 2021 - thelancet.com
Background Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …
[HTML] nih.gov

[HTML][HTML] Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis

CT Bramante, NE Ingraham, TA Murray… - The Lancet. Healthy …, 2021 - ncbi.nlm.nih.gov
Background Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …
[HTML] sciencedirect.com

[HTML][HTML] Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis

CT Bramante, NE Ingraham, TA Murray… - The Lancet Healthy …, 2021 - Elsevier
Background Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …
[PDF] sld.cu

[PDF][PDF] Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis

CT Bramante, NE Ingraham, TA Murray, S Marmor… - 2020 - covid19.sld.cu
Background Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors
for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory …